FDA Rejects Epidermolysis Bullosa Cell Therapy and Requests Additional Manufacturing Data
source: shutterstock.com

FDA Rejects Epidermolysis Bullosa Cell Therapy and Requests Additional Manufacturing Data

Clinical-stage biotechnology company Abeona Therapeutics ("Abeona") is working to develop a novel cell therapy for people living with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder characterized by…

Continue Reading FDA Rejects Epidermolysis Bullosa Cell Therapy and Requests Additional Manufacturing Data
Zeposia Trial for Crohn’s Disease Falls Short
source: pixabay.com

Zeposia Trial for Crohn’s Disease Falls Short

Zeposia (ozanimod), developed by Bristol Myers Squibb, is an orally administered sphingosine 1-phosphate (S1P) receptor that is currently approved for two separate indications: relapsing multiple sclerosis and ulcerative colitis. According…

Continue Reading Zeposia Trial for Crohn’s Disease Falls Short
Health Canada Accepts Priority Review of New Drug Submission for Exa-cel for Sickle Cell Disease and Beta Thalassemia
source: shutterstock.com

Health Canada Accepts Priority Review of New Drug Submission for Exa-cel for Sickle Cell Disease and Beta Thalassemia

Exa-cel Gene-Edited Therapy Vertex Pharmaceutical recently announced that Health Canada has accepted its New Drug Submission and granted Priority Review for Exa-cel, a gene-edited cell therapy, for the treatment of…

Continue Reading Health Canada Accepts Priority Review of New Drug Submission for Exa-cel for Sickle Cell Disease and Beta Thalassemia
Investigational Treatment for ADPKD Earns FDA’s Orphan Drug Designation
source: pixabay.com

Investigational Treatment for ADPKD Earns FDA’s Orphan Drug Designation

Approximately 540,000 individuals in the United States have been diagnosed with autosomal dominant polycystic kidney disease (ADPKD). The disease causes persistent and rapidly accumulating cysts to grow in the patient’s…

Continue Reading Investigational Treatment for ADPKD Earns FDA’s Orphan Drug Designation
Is the CDC Botching its RSV Vaccine Rollout?
source: shutterstock.com

Is the CDC Botching its RSV Vaccine Rollout?

  • Post author:
  • Post category:RSV

Last fall, a new vaccine for respiratory syncytial virus (RSV) intended for pregnant people was made available to the public. Physician Sarah Turner, who was used to getting some pushback…

Continue Reading Is the CDC Botching its RSV Vaccine Rollout?
Gene Therapy Led to “Robust Microdystrophin Expression” in Duchenne Muscular Dystrophy Patient
source: pixabay.com

Gene Therapy Led to “Robust Microdystrophin Expression” in Duchenne Muscular Dystrophy Patient

Duchenne muscular dystrophy (DMD) is an inherited disease that weakens a child’s muscles and eventually spreads throughout the child’s body. DMD is caused by mutations in the gene that helps…

Continue Reading Gene Therapy Led to “Robust Microdystrophin Expression” in Duchenne Muscular Dystrophy Patient
First Treatment Approved for Nonalcoholic Steatohepatitis Liver Scarring
source: shutterstock.com

First Treatment Approved for Nonalcoholic Steatohepatitis Liver Scarring

According to a press release from the US Food and Drug Administration (FDA), the agency has approved the medication resmetirom (marketed as Rezdiffra) as the first-ever treatment intended to treat…

Continue Reading First Treatment Approved for Nonalcoholic Steatohepatitis Liver Scarring
Doctors Transplant Genetically Edited Pig Kidney Into 62-Year-Old Man with End-Stage Kidney Disease
source: shutterstock.com

Doctors Transplant Genetically Edited Pig Kidney Into 62-Year-Old Man with End-Stage Kidney Disease

Over 100,000 individuals living in the U.S. are on a waiting list for an organ transplant. An average of 17 people die each day while waiting for a donor organ.…

Continue Reading Doctors Transplant Genetically Edited Pig Kidney Into 62-Year-Old Man with End-Stage Kidney Disease
Eosinophilic Esophagitis Patients Are Seeing Improved Treatment Options
Photo courtesy of Towfiqu Barbhuiya on Unsplash

Eosinophilic Esophagitis Patients Are Seeing Improved Treatment Options

Recently, the US Food and Drug Administration (FDA) approved a label expansion for the monoclonal antibody dupilumab (marketed as Dupixent) in the treatment of a rare disease called eosinophilic esophagitis…

Continue Reading Eosinophilic Esophagitis Patients Are Seeing Improved Treatment Options